Emerging Therapies Using Inhaled RNA Therapeutics for Chronic Respiratory Disorders

Abstract

The advent of RNA-based therapeutics marks a paradigm shift in the management of chronic respiratory disorders, particularly with the innovation of inhaled delivery systems. This review synthesizes current evidence regarding the mechanistic rationale, clinical potential, and translational challenges of inhaled RNA therapeutics including siRNA, mRNA, and antisense oligonucleotides in conditions such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and idiopathic pulmonary fibrosis (IPF). Recent studies demonstrate that inhaled RNA agents can precisely modulate pulmonary gene expression, offering unprecedented opportunities for disease modification. The article details the epidemiological context, disease mechanisms, clinical manifestations, and diagnostic strategies of chronic respiratory disorders, before exploring the advances and practical considerations of inhaled RNA therapeutics. Finally, we discuss the implications of emerging guideline recommendations and highlight future directions for translational application.

Introduction

Chronic respiratory disorders represent a significant global health burden, characterized by progressive morbidity, reduced quality of life, and substantial healthcare utilization. Traditional pharmacological interventions, while effective in symptom management, often lack disease-modifying capabilities and are limited by systemic adverse effects. The exploration of RNA-based therapies particularly those delivered directly to the lungs via inhalation offers a promising approach to address both the underlying pathophysiology and unmet clinical needs in chronic airway diseases. This review aims to provide clinicians and researchers with an up-to-date, evidence-based synthesis of inhaled RNA therapeutics and their evolving role in respiratory medicine.

Epidemiology / Disease Burden

Chronic respiratory diseases, including asthma, COPD, CF, and IPF, collectively affect over 500 million individuals worldwide. COPD is now the third leading cause of death globally, while asthma prevalence continues to rise, particularly in urbanized regions. CF, though rarer, leads to significant morbidity in affected individuals, and IPF remains a devastating disorder with limited therapeutic options. The economic burden of these diseases is profound, driven by hospitalizations, lost productivity, and the need for long-term pharmacotherapy. Despite advances in inhaler technology and biologics, disease progression and exacerbations remain common, underscoring the need for novel, targeted interventions.

Pathophysiology

The pathophysiology of chronic respiratory disorders is multifactorial, involving genetic susceptibility, environmental exposures, immune dysregulation, and aberrant cellular signaling. In asthma and COPD, airway inflammation, remodeling, and hyperresponsiveness play central roles, whereas CF is driven by mutations in the CFTR gene leading to viscous secretions and recurrent infection. IPF is characterized by progressive fibrosis due to dysregulated wound healing and aberrant epithelial-mesenchymal signaling. Traditional therapies often target downstream inflammatory mediators; however, RNA therapeutics allow for upstream, gene-specific modulation, which could arrest or even reverse pathogenic processes at their source.

Risk Factors

Key risk factors vary across chronic respiratory diseases. Tobacco smoke remains the primary risk for COPD, while environmental pollutants, occupational exposures, and genetic predisposition contribute to asthma and IPF. CF is inherited in an autosomal recessive fashion, with carrier status influencing disease severity. Increasing age, male gender, and comorbidities such as cardiovascular disease further compound risk profiles. Understanding these factors is crucial for patient stratification and for identifying individuals most likely to benefit from novel RNA-based approaches.

Clinical Features

Patients with chronic respiratory disorders typically present with persistent cough, dyspnea, wheezing, sputum production, and, in advanced stages, respiratory failure. Exacerbations acute worsening of symptoms are common and are associated with accelerated lung function decline and increased mortality. In CF, recurrent pulmonary infections and failure to thrive are hallmark features, while IPF presents insidiously with dry cough and progressive exertional breathlessness. The heterogeneity in clinical presentation necessitates precise diagnostic workup and individualized management strategies.

Diagnosis

Diagnosis of chronic respiratory diseases relies on a combination of clinical assessment, spirometry, imaging, and laboratory evaluation. Pulmonary function testing remains central for asthma and COPD, enabling detection of airflow limitation and reversibility. High-resolution computed tomography (HRCT) is essential for IPF diagnosis, revealing characteristic fibrotic patterns. Molecular genetic testing is requisite for CF, identifying specific CFTR mutations. Biomarker development including gene expression profiling offers potential for earlier detection and for monitoring therapeutic response to RNA-based interventions.

Treatment & Management

Conventional therapies include inhaled corticosteroids, bronchodilators, mucolytics, antibiotics, and, in select cases, biologic agents targeting IgE or interleukin pathways. Pulmonary rehabilitation, vaccination, and smoking cessation are mainstays of supportive care. Nonetheless, these treatments are largely palliative, with limited efficacy in preventing long-term decline or addressing the underlying molecular drivers of disease. The need for targeted, disease-modifying therapies is particularly acute in refractory cases or in genetically defined conditions such as CF.

Recent Advances / Emerging Therapies

Inhaled RNA therapeutics have emerged as a transformative technology in respiratory medicine. Small interfering RNAs (siRNAs), messenger RNAs (mRNAs), and antisense oligonucleotides (ASOs) can be formulated for aerosolized delivery, allowing for localized, cell-specific modulation of gene expression in the lung. Preclinical and early-phase clinical studies have demonstrated robust target knockdown and restoration of defective protein function, notably in CF (e.g., mRNA therapies for CFTR correction) and in silencing proinflammatory cytokines in asthma and COPD. Lipid nanoparticles and biodegradable polymers are under investigation to optimize pulmonary deposition and minimize off-target effects. Despite challenges related to mucociliary clearance and immune activation, recent advances in vector design have markedly improved the safety and efficacy profiles of inhaled RNA agents. Ongoing trials are evaluating the efficacy of these therapies in modifying disease progression, reducing exacerbation rates, and improving quality of life.

Guideline Recommendations

While inhaled RNA therapeutics remain investigational, international guidelines increasingly recognize the importance of precision medicine and the potential for gene-targeted interventions. The Global Initiative for Asthma (GINA) and GOLD (Global Initiative for Chronic Obstructive Lung Disease) stress the need for ongoing research and incorporation of novel agents in refractory or genetically stratified populations. For CF, the Cystic Fibrosis Foundation has endorsed the exploration of RNA-based therapies as adjuncts or alternatives to current CFTR modulators. Expert consensus highlights the importance of multidisciplinary collaboration, rigorous clinical trial design, and long-term pharmacovigilance as these therapies approach clinical translation.

Conclusion

Inhaled RNA therapeutics represent a promising frontier in the treatment of chronic respiratory disorders, offering the potential for disease-modifying effects through precise molecular targeting. Advances in delivery systems and nucleic acid chemistry have addressed many early limitations, paving the way for translational application in asthma, COPD, CF, and IPF. Continued research is needed to define optimal patient selection, long-term safety, and integration into existing care pathways. As these novel therapies progress through clinical development, they hold the potential to reshape the landscape of respiratory medicine, transforming outcomes for millions of patients worldwide.